Sanofi Wins Crucial Tax Case In India Linked To Shantha Deal; Averts Charges Of Up To $170 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s deal for India’s Shantha Biotechnics was under the spotlight as India’s Income Tax department alleged that the deal was structured with an intention to avoid taxes. The decision may clear hurdles for other MNCs acquiring Indian companies.
You may also be interested in...
India's Income Tax Department Tightens Noose Over Sanofi-Aventis' Shantha Biotech Deal; Claim Tax On Deal Made Over An "Indian" Asset
MUMBAI - Sanofi-Aventis is faced with more headwinds in India even as it tries to absorb the negative impact of the recent delisting of Shan 5 - its popular pentavalent vaccine - by the World Health Organization
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.